AI in practice: 4 real-world use cases in health and life sciences
March 5, 2026 |
Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it is applied to clearly defined challenges, embedded into existing workflows, and paired with deep domain expertise.
Across health and life sciences, organizations are moving beyond experimentation and focusing on how AI can support better decisions, more efficient operations, and clearer communication. At Inizio, these capabilities are central to how we drive Intelligent Commercialization™ – connecting data, insight, and expertise to help teams act with greater clarity and confidence. The following four use cases from across Inizio illustrate what that looks like in real-world settings – supporting operational performance, insight generation, engagement strategies, and strategic decision-making across the commercialization journey.
How did Inizio Engage scale call monitoring with AI-powered speech analytics?
Traditional call monitoring approaches often limit both scale and consistency, with only a small proportion of interactions reviewed and feedback delivered retrospectively. In this use case, Inizio Engage applied AI-powered speech analytics to analyze calls at scale, enabling patterns, risks, and performance indicators to be identified more efficiently and consistently across large volumes of interactions.
By automating the analysis of call content, our client was able to move beyond manual sampling and focus attention where it mattered most. The approach supported more targeted coaching and quality assurance, helping improve agent performance while maintaining oversight across a significantly broader set of calls.
How did Inizio Evoke turn digital insights into smarter HCP engagement with hematologic oncologists?
Engaging hematologic oncologists effectively requires a clear understanding of how they seek, consume, and respond to information. In this example, Inizio Evoke used Narratev™, a product in their Cognitev™ platform, to uncover real-world engagement behaviors, moving beyond surface-level metrics to identify patterns that could inform more relevant and timely interactions.
By translating these insights into practical recommendations, our client was able to align engagement strategies more closely with oncologists’ information needs and preferences. This helped support more focused decision-making and enabled engagement approaches that were better grounded in observable behavior rather than assumptions.
How did Inizio Ignite accelerate indication strategy in rare endocrine disorders?
Developing an effective indication strategy in rare endocrine disorders requires teams to assess a wide range of potential opportunities while balancing scientific feasibility, commercial considerations, and internal alignment. In this example, Inizio Ignite used AssetNav, part of their Navigator AI™ platform, to evaluate and prioritize potential indications, enabling more informed and objective strategic discussions.
By applying consistent criteria and integrating insights across functions, teams were able to narrow a broad set of possibilities into a focused, prioritized shortlist. This supported clearer decision-making, faster alignment, and a more repeatable approach to indication planning that could be applied beyond a single strategic exercise.
How did Inizio Medical elevate MSL performance with AI-enabled field intelligence?
Medical Science Liaisons (MSLs) generate vast amounts of valuable insight through their interactions with healthcare professionals, yet much of this intelligence can be difficult to capture, structure, and apply consistently. Inizio Medical built iON AI™ HCP Interact to help transform unstructured field insights into actionable intelligence that could be shared across medical and commercial teams.
By using AI to synthesize insights from MSL activity, organizations can surface emerging themes, identify unmet needs, and support more consistent scientific exchange. This enables MSLs to spend less time on manual reporting and more time on high-value engagement, with clearer visibility into field insights to inform strategy and planning.
Taking AI from potential to practice
The impact of AI is not defined by the technology alone, but by how it is applied to real challenges and real decisions. When paired with human expertise and grounded in strong data foundations, AI becomes a powerful enabler of more focused action and measurable progress.
Rather than replacing existing processes, each example shows AI working alongside teams – extending their ability to monitor, understand, and act at scale. This is how Inizio helps organizations drive Intelligent Commercialization™ – using platforms, products, and solutions to turn insight into action and complexity into clarity across the pharma lifecycle.
Discover how Intelligent Commercialization™ is built to deliver real-world results.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...
Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets
In emerging markets where primary care systems do not exist, the patient is the only constant in the journey
PEGASUS JOINS ASHFIELD HEALTHCARE COMMUNICATIONS
Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider...
Living with Crohn’s Report
Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?
Infographic: Research Partnership
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
AAD conference 2016
Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients
Video: Global Biosimilars Market
Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch
Case study: Understanding Patient Willingness to Pay in Emerging Markets
Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...
From promise to practice: immuno-oncology in action Part 3 – Emerging Markets
Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.
It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016
Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...